Haskell CM - Search Results

1

p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.

Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. Porter PL, et al. Among authors: haskell cm. J Natl Cancer Inst. 2006 Dec 6;98(23):1723-31. doi: 10.1093/jnci/djj467. J Natl Cancer Inst. 2006. PMID: 17148774 Free PMC article. Clinical Trial.

2

Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.

Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Tubbs R, et al. J Clin Oncol. 2009 Aug 20;27(24):3881-6. doi: 10.1200/JCO.2008.20.1566. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620488 Free PMC article.

3

Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.

Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Harigopal M, et al. Am J Pathol. 2010 Apr;176(4):1639-47. doi: 10.2353/ajpath.2010.090711. Epub 2010 Feb 11. Am J Pathol. 2010. PMID: 20150438 Free PMC article. Clinical Trial.

4

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Linden HM, et al. Among authors: haskell cm. J Clin Oncol. 2007 Feb 20;25(6):656-61. doi: 10.1200/JCO.2006.07.0847. J Clin Oncol. 2007. PMID: 17308269 Clinical Trial.

5

Systemic therapy for micrometastatic breast cancer.

Lindgren T, Haskell CM. Lindgren T, et al. Among authors: haskell cm. Cancer Invest. 1987;5(3):205-13. doi: 10.3109/07357908709011737. Cancer Invest. 1987. PMID: 2443225 Review. No abstract available.

6

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J. Ganz PA, et al. Among authors: haskell cm. Cancer. 1989 Apr 1;63(7):1271-8. doi: 10.1002/1097-0142(19890401)63:7<1271::aid-cncr2820630707>3.0.co;2-6. Cancer. 1989. PMID: 2465815 Clinical Trial.

7

Genetic analysis and midline malignancies of uncertain origin.

Haskell CM. Haskell CM. J Natl Cancer Inst. 1991 Mar 6;83(5):314-5. doi: 10.1093/jnci/83.5.316. J Natl Cancer Inst. 1991. PMID: 1995912 No abstract available.

8

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer.

Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Ganz PA, et al. Among authors: haskell cm. Cancer. 1988 Feb 15;61(4):849-56. doi: 10.1002/1097-0142(19880215)61:4<849::aid-cncr2820610435>3.0.co;2-b. Cancer. 1988. PMID: 3276389 Clinical Trial.

9

Phase I trial of extracellular adenosine 5'-triphosphate in patients with advanced cancer.

Haskell CM, Wong M, Williams A, Lee LY. Haskell CM, et al. Med Pediatr Oncol. 1996 Sep;27(3):165-73. doi: 10.1002/(SICI)1096-911X(199609)27:3<165::AID-MPO6>3.0.CO;2-C. Med Pediatr Oncol. 1996. PMID: 8699994 Clinical Trial.

10

Non-small cell lung cancer.

Haskell CM, Holmes EC. Haskell CM, et al. Dis Mon. 1988 Feb;34(2):53-108. doi: 10.1016/0011-5029(88)90024-7. Dis Mon. 1988. PMID: 2834155 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters